Study details
Enrolling now
A Phase 1 Trial to Test a New Drug
TIXiMED, Inc.
NCT IDNCT06800729ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Target enrollment
35
Study length
about 4 months
Ages
18–70
Locations
1 site in CA
What this study is about
This trial is testing the safety, tolerability, and how your body processes TIX100 in healthy adults. Participants will receive either a placebo or TIX100 orally for 120 days.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Placebo
- 2.Take TIX100, an orally available inhibitor of thioredoxin-interacting protein
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
OralOral
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug routes
oral
Endpoints
Primary: Number of participants with treatment-related adverse events as assessed by CTCAE v5.0